Herantis Pharma Plc ((FI:HRTIS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Herantis Pharma Plc has recently completed a clinical study titled Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients With Parkinson’s Disease. The study aimed to assess the safety and tolerability of HER-096, a potential treatment for Parkinson’s disease, by examining how the body interacts with the drug. This study is significant as it could pave the way for new therapeutic options for Parkinson’s disease patients.
The intervention being tested is HER-096, which is administered via subcutaneous injections. In Part 1 of the study, a single dose was given to healthy volunteers, while in Part 2, multiple doses were administered to Parkinson’s disease patients over four weeks, with a placebo group for comparison.
The study was designed as a randomized, sequential intervention model. Part 1 was open-label, while Part 2 was double-blind, randomized, and placebo-controlled, ensuring robust data collection. The primary purpose of the study was treatment-focused.
The study began on October 11, 2024, and was completed by September 11, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which can influence the timing of potential market entry.
The completion of this study could positively impact Herantis Pharma’s stock performance as it demonstrates progress in developing a new treatment for Parkinson’s disease. This could enhance investor sentiment, especially if the results are favorable compared to competitors in the neurodegenerative disease treatment market.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.